Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C

Abstract

Background. Depressive symptoms are frequent side effects of interferon α therapy (IFN-α). Both biological and psychological processes may occur concomitantly during hepatitis C treatment.Objectives. This study was carried out to determine the impact of biological (immune response) and psychological factors on formation of depressive symptoms and major depressive disorder (MDD) during hepatitis C treatment. Material and methods.A total of 99 patients receiving pegylated IFN-α and ribavirin for chronic C type hepatitis participated in the prospective cohort study. Symptoms of depression were assessed with the Montgomery-Åsberg Depression Rating Scale (MADRS) during treatment and 24 weeks after treatment. Neuroticism was measured with the Eysenck Personality Questionnaire -Revised (EPQ-R/N). Diagnosis of MDD was made using the Present State Examination (PSE-10) and DSM-IV-TR criteria. Factor analysis was used to detect factors adding up to total severity of depressive symptoms. Predictors of MDD were investigated using logistic regression analysis.Results. Factor analysis returned 3 factors: 1 st -MADRS scores at weeks 0-12, 2 nd -MADRS and N scores before treatment, 3 rd -MADRS at the 24 th week of treatment and 24 weeks after treatment. The total severity of depressive symptoms consisted of 3 components: personality-related before treatment, IFN-α-related during treatment and dependent on the effect of treatment. Regression analysis showed that a history of psychiatric disorders (OR = 4.8) and MADRS scores before treatment (OR = 1.25) were predictors of MDD, as opposed to level of neuroticism.Conclusions. The severity of depressive symptoms and MDD during the hepatitis C treatment was related to general depressive vulnerability, not to psychological factors related to neuroticism.

The Severity of Depressive Symptoms as an Independent Predictor of Sustained Virological Response During Treatment of Hepatitis C With Pegylated Interferon-α2a and Oral Ribavirin

“…According to Małyszczak et al (19), it was not neuroticism score but depressive symptoms severity before treatment that was associated with the severity of depressive symptoms among HCV patients during PEG-IFN-α2a treatment. A study by Frydecka et al (20) HCV is a primarily hepatotropic positive-strand RNA virus, but there may be various extrahepatic localizations of its replication, even in peripheral blood mononuclear cells (PBMCs) (22).…”

“…According to Małyszczak et al (19), it was not neuroticism score but depressive symptoms severity before treatment that was associated with the severity of depressive symptoms among HCV patients during PEG-IFN-α2a treatment. A study by Frydecka et al (20) revealed that baseline MADRS score and IL6 C-174G polymorphism are risk factors of MDD among patients with chronic hepatitis C treated by PEG-IFN-α2a.…”

HTR1A, TPH2, and 5-HTTLPR Polymorphisms and Their Impact on the Severity of Depressive Symptoms and on the Concentration of Tryptophan Catabolites during Hepatitis C Treatment with Pegylated Interferon-α2a and Oral Ribavirin (PEG-IFN-α2a/RBV)

“…One of the important factors is genetic polymorphism, which can increase individual vulnerability to depression. Some data show that it is not psychological factors but depressive vulnerability that is associated with the severity of depressive symptoms among HCV patients treated with IFN-α [ 16 ].…”